Recent advances in clinical development of leukotriene B4 pathway drugs.
Sign Up to like & getrecommendations! Published in 2017 at "Seminars in immunology"
DOI: 10.1016/j.smim.2017.08.007
Abstract: The LTB4 pathway is an attractive target for therapeutic drug development. Two broad classes of drugs have been pursued: antagonists of the primary LTB4 receptors (BLT1 and BLT2) and inhibitors of LTA4 Hydrolase (LTA4H), the… read more here.
Keywords: pathway drugs; advances clinical; pathway; recent advances ... See more keywords